Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | HMGCR | P04035 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7720729 | 0.94 | GCGR (0.86) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6953288 | 0.88 | GCGR (1.00) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6871563 | 0.86 | GCGR (0.74) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6747779 | 0.86 | GCGR (0.74) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL15029058 | 0.84 | GCGR (0.73) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL18947969 | 0.83 | GCGR (0.70) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL18947967 | 0.83 | GCGR (0.70) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2647903 | 0.83 | GCGR (1.00) | GCGR | |
| SCHEMBL3407031 | 0.83 | GCGR (0.69) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL7077308 | 0.82 | GCGR (0.67) | GCGRESR1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387566-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-05-07 | — | — | EP | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2011141934-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF HMG-COA REDUCTASE INHIBITORS | MATRIX LABORATORIES LTD. (IN) | 2011-11-17 | — | — | WO | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | GCGR 620/4885ESR1 3183/4885HMGCR 32/4885 |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | GCGR 1236/4885ESR1 1747/4885HMGCR 137/4885 |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | GCGR 1565/4885ESR1 2628/4885HMGCR 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.